A BCG2, also known as breast cancer resistance protein (BCRP), is a constitutively expressed ABC transporter with physiological roles in many tissues including the blood-brain and blood-testis barriers, the liver, the kidney and the mammary glands [1] [2] [3] [4] . Dysfunction of ABCG2 is linked to hyperuricemia, which can result in gout, kidney disease and hypertension, all of which are thought to be a consequence of the impaired transport of uric acid 5 . ABCG2, like its functional homologs ABCB1 (P-glycoprotein) and ABCC1 (MRP1), has a major protective role against xenobiotics. It affects the pharmacokinetics of many commonly used drugs, and its expression correlates with a poor prognosis and treatment outcome of certain cancers [6] [7] [8] [9] [10] . ABCG2 has broad substrate specificity, with a certain preference for flat, polycyclic, hydrophobic compounds [11] [12] [13] [14] [15] . Because of their potential value as adjuvants in the treatment of cancer and pharmacotherapy, extensive efforts have been directed over the past decades to the development of specific inhibitors against human ABCG2 and other multidrug ABC transporters 1, [16] [17] [18] [19] [20] . The fungal toxin fumitremorgin C (FTC) is a selective inhibitor of ABCG2 but has undesirable neurotoxic effects 16, 21, 22 . To reduce neurotoxicity, synthetic tetracyclic analogs of FTC have been developed. Among them, Ko143 was found to be more potent and less toxic than FTC, but it is not stable in mouse plasma and has been reported to have nonspecific effects on the transport activities of ABCB1 and ABCC1 at concentrations above 1 µ M
BCG2, also known as breast cancer resistance protein (BCRP), is a constitutively expressed ABC transporter with physiological roles in many tissues including the blood-brain and blood-testis barriers, the liver, the kidney and the mammary glands [1] [2] [3] [4] . Dysfunction of ABCG2 is linked to hyperuricemia, which can result in gout, kidney disease and hypertension, all of which are thought to be a consequence of the impaired transport of uric acid 5 . ABCG2, like its functional homologs ABCB1 (P-glycoprotein) and ABCC1 (MRP1), has a major protective role against xenobiotics. It affects the pharmacokinetics of many commonly used drugs, and its expression correlates with a poor prognosis and treatment outcome of certain cancers [6] [7] [8] [9] [10] . ABCG2 has broad substrate specificity, with a certain preference for flat, polycyclic, hydrophobic compounds [11] [12] [13] [14] [15] . Because of their potential value as adjuvants in the treatment of cancer and pharmacotherapy, extensive efforts have been directed over the past decades to the development of specific inhibitors against human ABCG2 and other multidrug ABC transporters 1, [16] [17] [18] [19] [20] . The fungal toxin fumitremorgin C (FTC) is a selective inhibitor of ABCG2 but has undesirable neurotoxic effects 16, 21, 22 . To reduce neurotoxicity, synthetic tetracyclic analogs of FTC have been developed. Among them, Ko143 was found to be more potent and less toxic than FTC, but it is not stable in mouse plasma and has been reported to have nonspecific effects on the transport activities of ABCB1 and ABCC1 at concentrations above 1 µ M 23 . Attempts have also been made to develop selective ABCG2 inhibitors derived from tariquidar, a third-generation ABCB1 inhibitor reported to be a potential substrate of ABCG2 (refs 20,24-28 ).
There is at present no structure of a human multidrug transporter bound to specific inhibitors. All of the above approaches aimed at developing specific inhibitors were made in the absence of structural insight into how the small compounds may interact with, modulate or inhibit ABCG2. Recently, the first structure of human ABCG2 revealed two cholesterol molecules bound at a central, inward-facing cavity, hinting at a potential location where substrates such as estrone-3-sulfate (E 1 S) might bind 29 . However, it remained unknown where inhibitors bind ABCG2 and whether a single or multiple ligand-binding sites exist, topics that are hotly debated [30] [31] [32] [33] [34] .
To address these questions, we determined single-particle cryo-EM structures of nanodisc-reconstituted human ABCG2 bound to distinct inhibitors. The high resolution obtained not only allowed the first de novo building of an atomic structure of the entire human ABCG2 protein, but also provided detailed insight into inhibition of the transporter by small molecules. By synthesizing a range of Ko143-derived compounds and testing their activity in vitro, we also obtained crucial information into the structure-activity relationship (SAR) of the Ko143 scaffold. Finally, we demonstrate that depending on the size of the compounds, one or two inhibitor molecules are required for full inhibition of ABCG2. These results provide an essential structural basis for future development of ABCG2 modulators.
for the synthesis of novel compounds (Fig. 1 , Supplementary Table  1 and Supplementary Notes). We mainly focused on modifications of the C-3 (R 2 ) and C-9 (R 1 ) positions of the Ko143 scaffold, because previous studies have demonstrated that the inhibitory capacities of FTC and its derivatives are affected by changes at these positions 16, 35 . Seventeen compounds were synthesized and screened in vitro for their ability to inhibit the E 1 S-stimulated ATPase activity and initial E 1 S transport activity of ABCG2 in proteoliposomes 29 , and similar trends were observed in the ranking of their inhibitory capacities (Fig. 1a,b and Supplementary Table 2). We found that five compounds were as potent as Ko143 or slightly superior. Compound MZ29, which contained an O-cyclopentyl group added to the C-9 position, was found to be the most potent inhibitor of ATPase activity and fully abolished E 1 S transport. In addition, similarly to Ko143 but unlike E 1 S, MZ29 had a significant thermostabilizing effect on ABCG2 ( Supplementary Fig. 1a ,b and Supplementary Table 3 ), suggesting that it caused conformational stabilization, and was therefore selected for structural studies.
For high-resolution structure determination by cryo-EM, we added the conformational antigen-binding fragment of the human-specific 5D3 antibody (Fab) to inhibitor-bound ABCG2 (refs 29, 36 ) (Figs. 2-4 and Supplementary Figs. 2-6 ). The addition of two Fabs increased the particle mass by ~100 kDa, which aided cryo-EM analysis, allowing for higher-resolution reconstruction. To rule out that the Fab altered the conformation of ABCG2 and diminished the mechanistic insight, we also determined the structure of MZ29-bound ABCG2 in the absence of Fab, which was found to be indistinguishable from the Fab-bound structure (below and Supplementary Figs. 7 and 8 ). Furthermore, we investigated whether Fab would affect the binding of a synthetic, fluorescent Ko143 derivative (FKo143) to ABCG2. FKo143 contains a fluorescent NBD group at the C-3 position, which did not alter its inhibitory capacity (Fig. 1a,b,d ), thus enabling us to measure its binding affinity by microscale thermophoresis (MST) (Fig. 1c and Supplementary Table 4) . By determining dissociation constants, we found that the binding of FKo143 to ABCG2 was unaffected by Fab, providing strong support for the structural data and highlighting the functional relevance of the inhibitor-bound ABCG2-Fab structures.
Structures of the ABCG2-MZ29 complexes. The structure of nanodisc-reconstituted ABCG2 bound to MZ29 and two Fabs (ABCG2-MZ29-Fab) was determined at an overall resolution of 3.1 Å (Table 1 , Fig. 2 and Supplementary Figs. 1-4) . The TMDs and the ABCG2-Fab interface were well resolved (resolution around 2.5 Å), allowing the identification of two bound MZ29 molecules (Fig. 2a,b and Supplementary Figs. 3 and 4) . The density for the nucleotide-binding domains (NBDs), which previously had only been modeled, owing to lower resolution 29 , was also of excellent quality ( Supplementary Fig. 4 ), allowing de novo building and thus providing the first complete atomic structure of human ABCG2. The conformation of the TMDs in the ABCG2-MZ29-Fab structure was found to be inward facing, similar to that of the previously ATPase activity (%) +MZ25  +MZ15  +Ko143  +Ko132  +FKo132  +MZ90  +MZ21  +MZ92  +MZ16  +MZ35  +MZ40  +MZ34  +MZ44  +MZ25  +MZ29  +MZ15  +MZ90  +MZ21  +FKo132  +FKo143  +Ko143  +Ko132  +MZ92  +MZ148  +MZ35  +FTC  +MZ16  +MZ34  +MZ44  +MZ40  +MZ148 +FTC +FKo143 determined ABCG2-cholesterol-Fab structure, with a slit-like cavity (cavity 1) accessible both from the cytoplasmic side of the membrane and from the inner leaflet of the lipid bilayer. Cavity 1 is separated from a second cavity (cavity 2) by a 'leucine plug' formed by L554 of opposing monomers (Fig. 2c,d ) and was previously shown to be optimally suited to bind relatively flat, hydrophobic, polycyclic molecules 29 , a feature that is distinct from the multidrug transporters ABCB1 and ABCC1, which form more globular cavities 37, 38 . Access to cavity 1 from the lipid bilayer occurs via a hydrophobic 'membrane entrance' lined by residues A397, V401, L405, L539, I543 and F547 from transmembrane (TM) helices TM1b and TM5a of opposing monomers (Fig. 2e,f) . The EM density clearly revealed two MZ29 molecules bound in cavity 1, each between TM1b and TM2 of one ABCG2 monomer and TM5a of the other.
The binding pockets are close to the two-fold symmetry axis of ABCG2, and the two MZ29 molecules occupy almost the entire volume of cavity 1, thereby preventing the binding of other molecules, such as transport substrates (Fig. 2b-d) . Cavity 2, which is fully occluded between the leucine plug and the extracellular loops, does not contain any density features, indicating that no ordered inhibitors or substrates are bound at this site.
At the bottom of cavity 1 (furthest from the cytoplasmic membrane boundary), the hydrophobic residues F431, F432, M549 and L555 interact with the O-cyclopentyl group of MZ29 (Fig. 2e) . In addition, the O-cyclopentyl groups of the two MZ29 molecules are 3.7 Å apart, probably forming van der Waals interactions with one another. T435 forms a hydrogen bond with the oxygen at the C-9 position, and a series of polar and hydrophobic residues, including S440, T542 and V546, form van der Waals interactions with the polycyclic core of MZ29. Furthermore, N436 forms a hydrogen bond with the NH group of the indole ring, and F439 forms a stacking interaction with the benzene ring of the indole moiety. Residues V401, L405, I543, V546 and F547 form van der Waals interactions with the isobutyl group at the C-12 position, whereas A397, V401, L539 and I543 interact with the tert-butyloxycarbonyl group at the C-3 position. Our functional analyses of synthetic Ko143 derivatives allowed us to probe the specific interactions between cavity 1 and the inhibitor in the context of wild-type ABCG2 (Supplementary Table 5 ).
The inhibitory capacity of the Ko143 derivatives was more affected by changes at the C-9 position than at the C-3 position (Fig. 1a,b,d ). Removal of the methoxy group at the C-9 position caused a ~22-fold reduction in binding affinity, as shown by differences in the dissociation constants measured for FKo143 versus FKo132 ( Fig. 1c and Supplementary Table 4 ). This reduction in affinity and in inhibitory potency (Ko143, FKo143 and MZ15 versus Ko132 and FKo132, Fig. 1a ,b) confirmed the importance of the hydrogen bond between the methoxy group of Ko143 and T435 in cavity 1 (refs 16, 21, 22, 35 ) (Fig. 2e) . Whereas small hydrophobic additions to the C-9 position (as in MZ25 and MZ29) did not affect potency, the addition of hydrophilic groups (MZ34, MZ44) led to inactive compounds, probably because of chemical mismatch with the hydrophobic ABCG2 surface at the bottom of the cavity. Removal of the methyl group at the C-9 position (MZ21) also caused a drop in potency, which could be due to the hydrophilicity of the resulting hydroxyl group or the absence of hydrophobic interactions with residues at the bottom of cavity 1. The exchange of the tert-butyloxycarbonyl end group of the substituent at the C-3 position with either a positively (as in MZ16) or a negatively charged (as in MZ35) moiety resulted in a substantial decrease in inhibitory capacity, probably due to the mismatch with the hydrophobic side chains in the vicinity of the membrane entrance (Fig. 2f) . Likewise, the expansion of the diketopiperazine ring by one carbon atom (MZ92, Supplementary Table 1 ) caused a marked reduction of potency, possibly because the tert-butyloxycarbonyl group of the side chain was shifted, reducing the number of van der Waals interactions. Intriguingly, the inversion of the C-12 position from the R to the S configuration completely eliminated the inhibitory capability of the resulting diastereoisomer (MZ40, Supplementary Table 1), most likely because of an ensuing steric clash with residue N436. Finally, we can rationalize why FTC is less potent than Ko143: the E ring of FTC, as well as MZ148, cannot form favorable interactions with residues at the membrane entrance, which reduces the inhibitory potencies of these compounds.
We also determined the cryo-EM structure of nanodiscreconstituted ABCG2 in complex with MZ29, but in the absence of Fab, (ABCG2-MZ29) at an overall resolution of 3.6 Å (Table 1 and Supplementary Figs. 7 and 8 ). With the exception of the external loop EL3, which is in direct contact with Fab, the structure was indistinguishable from that of the Fab-bound form, and no differences in side chain conformations were detected at this resolution ( Supplementary Fig. 8f ). Two MZ29 molecules were bound at exactly the same positions and in the same orientations as in the Fab-bound structure. However, the resolution was lower despite a much larger number of particles used in the 3D reconstruction, demonstrating that the use of 5D3-Fab facilitated structure determination at significantly higher resolution (Table 1 and Structure of the ABCG2-MB136-Fab complex. We sought to explore whether a different class of inhibitor could bind in the same pocket (cavity 1) as MZ29 or cholesterol. We synthesized and evaluated derivatives of tariquidar 28 , a compound developed as a specific inhibitor of ABCB1, but whose phase III trials were discontinued mainly because of chemotherapy-related toxicity 39 . During systematic modification of tariquidar ( Fig. 4a and Supplementary Notes), it was observed that selectivity was drastically shifted from ABCB1 to ABCG2 by small alterations of the substitution pattern at the aromatic core 40 . To improve metabolic stability, the labile amide moiety was replaced with a triazole ring, and 'pegylation' was used to improve water solubility 24, 26 . The resulting compound, MB136, is a novel fourth-generation modulator of ABCG2, containing a triazole core and a propionyl side chain on the phenyl ring (Fig. 4a ). MB136 and tariquidar inhibited E 1 S transport by proteoliposome-reconstituted ABCG2, but both were less potent than Ko143 and MZ29 (Fig. 4b  and Supplementary Table 2 ). Indeed, only at higher concentrations of MB136 and tariquidar was E 1 S transport fully abolished. MB136 thermostabilized ABCG2 to a similar extent as Ko143 or MZ29 ( Supplementary Fig. 1b and Supplementary Table 3) .
We determined the cryo-EM structure of nanodisc-reconstituted ABCG2 in complex with MB136 and Fab (ABCG2-MB136-Fab) at an overall resolution of 3.6 Å, with the best-resolved regions around 3.0 Å ( Table 1 , Fig. 4c-e and Supplementary Figs. 5 and 6 ). The EM map revealed a strong density feature in cavity 1, overlapping in location to where MZ29 or cholesterol were previously observed (Fig. 4f) . This density was distinct in shape from that observed for MZ29 and could only fit one MB136 molecule. The initial processing of the data with C2 symmetry resulted in an averaged density for MB136 that was very broad, especially close to the two-fold symmetry axis (Supplementary Fig. 6e ). When the data were reprocessed with C1 symmetry, asymmetric features appeared in the density that allowed us to place MB136 and pinpoint specific interactions ( Supplementary Fig. 6f ). The fact that the fit of the EM density was not as high for MB136 as that of MZ29 suggested that MB136, despite its inhibitory capability (Fig. 4b) , may have multiple modes of binding by moving or sliding within cavity 1. Cholesterol and phospholipids bound to the TMDs. The high resolution of the EM maps and the presence of a physiologically relevant mix of lipids in the nanodisc (brain polar lipid extract) allowed us to visualize and characterize ABCG2-lipid interactions. While ordered lipids were observed at similar locations in all three structures, we used the highest resolution structure (ABCG2-MZ29-Fab) for the building of the lipid molecules. Ordered membrane cholesterol and phospholipids form a belt around ABCG2, thus marking the boundary of the lipid bilayer and matching the hydrophobic protein surface (Fig. 5a ). It was previously demonstrated that membrane cholesterol has an essential role for ABCG2 function, and it has been proposed that ABCG2 is mainly localized in lipid rafts of the plasma membrane, where the cholesterol concentration is high 41, 42 . Thus, the ordered cholesterol molecules visualized in our structure are likely to be of functional importance. We identified five ordered cholesterol molecules per ABCG2 monomer, tightly bound in hydrophobic grooves. The best-ordered cholesterol is located between TM5b, TM5c and TM6b and interacts with a number of hydrophobic residues (Fig. 5) . Although the TMD architectures of G-subfamily ABC transporters are probably similar, this specific pocket for cholesterol on the ABCG2 surface appears unique because the interacting residues are not conserved (Fig. 5b) and because no cholesterol-binding groove was observed in the crystal structure of the human liver cholesterol transporter ABCG5/ABCG8 (hereafter abbreviated as G5G8) 43 . Although studies have suggested that residues L555-L558 of ABCG2 contribute to sterol binding or sensing 44 , it has been shown that the relevant motif was in fact not important for cholesterol binding by ABCG2 (ref. 45 ). Our structure reveals that residues L555-L558 are not facing the lipid bilayer but are located in the core of ABCG2 and are some 12 Å away from the closest ordered cholesterol molecule. Therefore, these residues cannot bind membrane cholesterol directly, and the reported effects are likely to be allosteric in nature. We were also able to dock five annular phospholipids per ABCG2 monomer, which we modeled as phosphatidylethanolamine (PE), owing to its abundance in the lipid extract used for nanodisc generation. Intriguingly, one of the phospholipids covers the membrane entrance of ABCG2 and must therefore move if a substrate or inhibitor requires access to cavity 1 from within the lipid bilayer (Fig. 5a) .
Insight into the nucleotide-binding domains.
The high resolution and conformational homogeneity of the inhibitor-bound ABCG2 structures allowed for a de novo build of the NBDs, with clear side chain density (Fig. 3 and Supplementary Fig. 4 ). In the absence of nucleotides, the NBDs are in a functionally 'open' conformation (apo state), with a gap between the catalytically relevant motifs. Nevertheless, the NBDs remain in contact, with approximately 680 Å 2 of buried surface. The contact point is formed mainly by residues preceding the NPxDF motif (289-NPADF-293 for ABCG2), which is conserved in all G-subfamily ABC transporters 44 (Fig. 3) . The overall fold of the NBDs is similar to that of G5G8, with an overall r.m.s. deviation (r.m.s.d.) of 2.3 Å and a sequence identity of 33% (ref. 43 ). The distance between the Walker A and ABC signature motifs is 16.9 Å in ABCG2 compared to the 16.5 Å for G5G8, suggesting a shared NBD spacing for all G-subfamily ABC transporters in the nucleotide-free state. The linker connecting the last α -helix of the NBDs, containing the C2 motif 46 , with TM1a is not visible in our maps, nor was it observed in the structure of G5G8, most likely because of its inherent flexibility.
The mutation Q141K is a reported single-nucleotide polymorphism (SNP) of ABCG2 associated with hyperuricemia and gout. It results in decreased expression or degradation of the protein, probably due to misfolding 47, 48 . Our structure shows that Q141 is located in the NBD on an α -helix adjacent to TM1a of the TMD, where it can form a hydrogen bond with N158, confirming the previous in silico predictions 31, 34 ( Supplementary Fig. 4e ). Given that this is a critical, non-covalent interaction between the NBD and TMD, our structures can rationalize the detrimental effect of this mutation on protein folding and function. Finally, it has also been suggested that C284, C374 and C438 form intramolecular disulfide bonds that are important for ABCG2 function 49 . Our structures reveal that these cysteines are distantly located, and their functional roles are therefore unrelated to disulfide bond formation.
Stoichiometry of small-molecule inhibition.
To validate our structural findings of two Ko143 derivatives (MZ29), but only one MB136 molecule bound to ABCG2, we investigated how many inhibitor molecules were required to impair the ATPase activity of ABCG2 in nanodiscs (Supplementary Table 2 ). We found that maximal inhibition was obtained at a ratio of one MB136 molecule for each ABCG2 homodimer. In contrast, two molecules of Ko143 were required for full inhibition (Fig. 6a) . These results are in full agreement with our structural data that reveal the same stoichiometries. We observed an ~50% inhibition of ATPase activity when the molar ratio of Ko143 to ABCG2 homodimer was 1:1. This finding can be interpreted in two ways: a single Ko143 may be bound to every ABCG2 homodimer, reducing its activity by 50%; alternatively, half of the ABCG2 homodimers may contain two bound Ko143 molecules and are completely inhibited, whereas the other half contain no inhibitor and are active. While the high affinity of MZ29 did not allow a direct observation, we propose that the latter explanation is more likely because positive cooperativity can be invoked.
Discussion
Our results represent the first structures of a human multidrug transporter bound to specific, small-molecule inhibitors. Both MZ29 and MB136 bind in the same cavity as the previously observed cholesterol molecules 29 . Cholesterol bound to cavity 1 either represents an analog of the bona fide substrate E 1 S in ABCG2 or is a known substrate in other G-subfamily ABC transporters. We therefore conclude that cavity 1 in ABCG2 represents a multidrug-binding site, although future substrate-bound structures are needed to validate the hypothesis that all substrates bind in this pocket. ABCG2 exhibits conformational rigidity within cavity 1, irrespective of the ligand bound, and we hypothesize that this reduces the spectrum of ligands that can bind to ABCG2. Nevertheless, binding of distinct molecules has drastically different consequences: when cholesterol was bound to cavity 1, the ATPase rate was fully stimulated 29 , whereas it was abolished when MZ29 or MB136 was bound. This finding demonstrates that even though the conformation of ABCG2 may be similar (inward open), and the shape of cavity 1 is conserved, the transporter readily distinguishes between substrates and inhibitors in the presence of ATP. Although cavity 1 can bind one or two inhibitors symmetrically or asymmetrically, depending on their size and shape, it remains to be demonstrated whether the same holds for substrates in a productive transport cycle, i.e., whether two substrates may be transported during a single cycle.
Recently, in silico models of human ABCG2 were reported 31, 34 that used the G5G8 crystal structure 43 as a modeling template. The G5G8 structure is different from that of ABCG2 in that it does not form a central, inward-facing cavity, a feature critical to the binding of small compounds in ABCG2, as revealed in this study. Based on the in silico model, mutagenesis experiments were conducted, and some of the mutants showed changes in ABCG2 function in a cellular context 34 . However, none of the tested side chains are located in cavity 1 or interact with the inhibitory compounds in our structures. The observed functional effects might therefore be due to allosteric interactions or possibly direct contacts with substrates when ABCG2 adopts a different conformation from the inward-facing state reported here.
It is widely accepted that binding affinity is a key determinant of whether a molecule will be a transported substrate or an inhibitor without 'measurable' transport. Indeed, many substrates for ABCG2 have affinities in the low micromolar range 29, 50, 51 , whereas potent inhibitors, such as Ko143, have low nanomolar dissociation constants or IC 50 values [24] [25] [26] . We observed an ~3,000-fold difference in affinity between E 1 S 29 and FKo143 (Fig. 1c and Supplementary Table 4) . We speculate that substrates would bind in cavity 1 before moving toward cavity 2 in order to be transported, whereas inhibitors would remain tightly bound in cavity 1 without detectable transport. Because of the conformational coupling of the TMDs and NBDs, the movement of substrate is a prerequisite for the closing of cavity 1, the conversion of the TMDs to an inward-closed conformation and the concomitant closure of the NBD dimer. In a productive transport cycle, NBD-dimer closure is expected to result in the conversion of ABCG2 from an inward-to an outward-facing conformation, followed by hydrolysis of ATP and the release of substrate to the outside (alternating-access mechanism). The effect of inhibitors binding to cavity 1 would be twofold. First, given their higher affinities, the binding of substrates is prevented by the inhibitors as they almost completely occupy the volume provided by cavity 1. In this sense, the inhibitors presented here act competitively. Whereas less potent inhibitors, such as MB136, may move or slide within the cavity, the more potent inhibitor MZ29 showed no signs of any motion within cavity 1. Second, both MZ29 and MB136 appear to lock the inward-facing state of the TMDs, which prevents closure of the NBDs due to conformational coupling, as evidenced by the inhibition of ATPase activity upon inhibitor binding (Figs. 1a and 6 ). Such tight conformational coupling might be due to the compact shape of ABCG2, which does not provide the same flexibility as the more elongated architectures of ABC transporters of the B and C subfamilies.
The inhibitor-bound structures of ABCG2 presented here should prove useful for guiding future functional experiments. They also provide a long-sought basis for rational, structure-based inhibitor development against ABCG2. To understand the specific requirements of transported substrates, novel structures of substratebound states in distinct conformations are required.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0049-1.
Expression and purification of human ABCG2. Human ABCG2, containing an amino (N)-terminal Flag tag, was expressed in HEK293-EBNA (Thermo Fisher Scientific) cells 52 and purified as described previously 29 . After transfection, the cells were solubilized with 1% n-dodecyl-β -d-maltopyranoside (DDM) and 0.1% cholesteryl hemisuccinate (CHS) (w/v) (Anatrace), ultracentrifuged at 100,000g, and the supernatant was then incubated with anti-Flag M2 affinity agarose gel (Sigma). ABCG2 was eluted with Flag peptide (Sigma), loaded into a Superdex 200 10/300 column (GE Healthcare) pre-equilibrated with 40 mM HEPES, pH 7.5, 150 mM NaCl, 0.026% DDM and 0.0026% CHS (w/v), and the peak fractions were collected.
Size-exclusion chromatography-based thermostability assay (SEC-TS).
Detergent-purified ABCG2 was incubated with or without 10 µ M of inhibitor (MZ29, MB136 or Ko143) or 50 µ M of transport substrate (E 1 S) for 10 min at room temperature. 100 µ l samples were aliquoted into thin-walled PCR tubes and heated at one temperature, ranging from 30-75 °C, for 10 min in a Bio-Rad Thermocycler. The samples were cooled on ice immediately, spun at 100,000g for 20 min at 4 °C and then loaded onto a TSKgel G3000SWXL column (Tosoh Bioscience). Curves were plotted using the sigmoidal dose-response (variable slope) tool in GraphPad Prism 7 (GraphPad Software).
Expression and purification of 5D3-Fab. 5D3 hybridoma cells, producing the 5D3 monoclonal antibody, were obtained from B. Sorrentino 36 . The cells were cultured in WHEATON CELLine Bioreactors, according to the manufacturer's protocol, and 5D3-Fab was then purified from the supernatant, as described in the Fab Preparation Kit protocol (Thermo Fisher Scientific).
ABCG2-nanodisc preparation. Membrane scaffold protein (MSP) 1D1 was expressed and purified as described previously 53 . Brain polar lipid (BPL)/CHS (4:1) (w/w) was solubilized with a 3 × molar excess of sodium cholate using a ultrasonic bath. Solubilized BPL/CHS (4:1) (w/w) was mixed with MSP 1D1 and detergentpurified ABCG2 at a molar ratio of 100:5:0.2 (lipid/MSP/ABCG2). BioBeads were added, and the sample was incubated at 4 °C overnight. BioBeads were removed, and the sample was spun at 100,000g before being loaded into a Superdex 200 10/300 column (GE Healthcare) pre-equilibrated with 25 mM HEPES, pH 7.5, and 150 mM NaCl and used for ATPase assays. For cryo-EM studies in the presence of Fab, the sample was prepared as described above except ABCG2 was first mixed with a three-fold molar excess of Fab and then 10 µ M inhibitor (MZ29 or MB136) before reconstitution into nanodiscs. For cryo-EM studies in the absence of Fab, the sample was mixed with 10 µ M MZ29 before reconstitution.
ABCG2-liposome preparation.
A BPL/cholesterol (BPL/chol) (Avanti Polar Lipids) mixture was prepared at a 4:1 (w/w) ratio as described previously 54 . Briefly, the BPL/chol mixture was extruded through a 400-nm polycarbonate filter and destabilized with 0.17% (v/v) Triton X100. Detergent-purified ABCG2 was then mixed with BPL/chol at a 100:1 (w/w) lipid/protein ratio. Detergent was removed with BioBeads, and proteoliposomes were spun at 100,000g, resuspended in 25 mM HEPES, pH 7.5, 150 mM NaCl at a final lipid concentration of 10 mg ml −1 , and the reconstitution efficiency was determined 55 .
Transport assays. ABCG2 proteoliposomes were extruded through a 400-nm polycarbonate filter and diluted to 4 mg ml −1 lipid in 25 mM HEPES, pH 7.5, 150 mM NaCl. 5 mM MgCl 2 and 50 μ M [ 3 H]E 1 S was added, in the absence or presence of 0.5 μ M of unlabeled competitor (with the exception of MB136* and tariquidar* in Fig. 4b , where 10 μ M was used), and incubated for 5 min at 30 °C. The transport reaction was initiated by the addition of 2 mM ATP. To stop the reaction, samples were removed, added to ice-cold stop buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 100 μ M unlabeled E 1 S) and filtered using a Multiscreen vacuum manifold (MSFBN6B filter plate, Millipore). Radioactivity trapped on the filters was measured using a Perkin Elmer 2450 Microbeta2 microplate scintillation counter. Curves were plotted using the nonlinear regression Michaelis-Menten analysis tool and initial transport rates from 30 s to 2 min were determined using linear regression in GraphPad Prism 7. Rates were corrected for the orientation of ABCG2 in proteoliposomes as determined and described in ref. 29 . The normalized initial transport rates, with the uninhibited rates set to 100%, were then plotted.
ATPase assays. ATP hydrolysis activity was measured using a technique described previously 56 . All reactions were performed at 37 °C in the presence of 2 mM ATP and 10 mM MgCl 2 . For ATPase assays in proteoliposomes, experiments were completed with 50 µ M E 1 S in the presence or absence of 0.5 µ M competitor. For assays in ABCG2 nanodiscs, the molar ratios of Ko143 or MB136 were varied in relation to ABCG2 to determine the functional stoichiometry for both compounds. ATPase rates were determined using linear regression in GraphPad Prism 7. Rates were corrected for the orientation of ABCG2 in proteoliposomes as determined and described in ref. 29 .The normalized ATPase rates, with the uninhibited rates set to 100%, were then plotted.
Microscale thermophoresis binding assay (MST).
The binding of FKo143 (G2 + FKo143) or FKo132 (G2 + FKo132) to ABCG2 or ABCG2-Fab was measured using microscale thermophoresis with a NanoTemper monolith NT.115 instrument 57 . A range of concentrations of detergent-purified ABCG2 (0.11 nM-3.65 µ M) were incubated with 50 nM of FKo143 or FKo132 for 10 min in assay buffer (40 mM HEPES, pH 7.5, 150 mM NaCl, 0.026% DDM and 0.0026% CHS). To check the effect of 5D3-Fab on the binding of FKo143 to ABCG2, two separate samples were measured. In the first sample, ABCG2 was first preincubated with a 2.5 × molar excess of 5D3-Fab for 10 min prior to the addition of FKo143 (G2 + Fab + FKo143). In the second sample, ABCG2 was first preincubated with FKo143 for 10 min prior to the addition of 5D3-Fab (G2 + FKo143 + Fab). The samples were then loaded into NanoTemper standard glass capillaries, and microthermophoresis was carried out using 60% LED power and 40% MST. K D values were calculated using the mass action equation via the NanoTemper software.
Sample preparation and cryo-EM data acquisition. The cryo grids were prepared using a Vitrobot Mark IV (FEI) with the environmental chamber set at 100% humidity and 4 °C. An aliquot of 4 μ l purified ABCG2-MZ29-Fab, ABCG2-MB136-Fab or ABCG2-MZ29, at a protein concentration of approximately 0.4 mg ml
Model building and refinement. For model building, we used the post-processed map of ABCG2-MZ29-Fab at an overall resolution of 3.1 Å. The quality of the EM density was of excellent quality and allowed the de novo building of ABCG2 and the variable domain of 5D3-Fab. The Coot program 64 was used for all model building steps and the previous ABCG2-5D3(Fab) model (PDB 5NJ3 and PDB 5NIV) was docked into the EM density and used as an initial reference 29 . The MZ29 coordinates and restraints were generated using eLBOW 65 and fitted into the EM density using Coot. The complete ABCG2-MZ29-Fab atomic model was refined against the working map in Phenix 66 using the program phenix.real_space_ refine at a resolution limit of 3.1 Å. For the final round of model refinement, we performed global real-space refinement with standard geometry restraints as well as rotamer, Ramachandran plot, Cβ , noncrystallographic symmetry (NCS) and secondary structure restraints, coupled to reciprocal-space refinement of the B factors. The quality of the final model was analyzed using MolProbity 67 , and the refinement statistics are in Table 1 . For validation of the refinement, random shifts (mean value of 0.3 Å) were introduced into the coordinates of the final refined model using the program phenix.pdbtools 66 , then refinement was done with phenix.real_space_refine (using the same parameters as described previously) against the first unfiltered half-map (half-map 1). The overlay between the FSC curve of the model with random displacements refined against half-map 1 versus half-map 1 and the FSC curve of the same model versus half-map 2 (against which it was not refined) indicated that no over-refinement took place.
For the ABCG2-MZ29 structure, we used the ABCG2-MZ29 subcomplex structure, obtained from the ABCG2-MZ29-Fab sample, as a starting model for rebuilding into the post-processed and RELION local-resolution filtered maps. The structure was very similar with the exception of EL3, which needed rebuilding. After manual rebuilding in Coot, the structure was refined and validated similarly to the ABCG2-MZ29-Fab structure.
For the ABCG2-MB136-Fab structure, we docked the refined ABCG2-Fab subcomplex structure, obtained from the ABCG2-MZ29-Fab sample, into the EM density using Coot. The MB136 coordinates and restraints were generated using eLBOW and fitted into the EM density using Coot. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity. 
Data exclusions
Describe any data exclusions. No data excluded
Replication
Describe whether the experimental findings were reliably reproduced.
All replicates were successful
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Animals and humans were not used in the study, not applicable
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Animals and humans were not used in the study, blinding not applicable Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
